The following chemotherapy and immunotherapy combinations are available for the treatment of lung cancer in England:
- Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (National Institute for Health and Care Excellence (NICE) Technology Appraisal 600) [available via the Cancer Drugs Fund];
- Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NICE Technology Appraisal 577) [available via the Cancer Drugs Fund];
- Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (NICE Technology Appraisal 368); and
- Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (NICE Technology Appraisal 584).